Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults

ACP has issued an update of its guideline with clinical recommendations for treatments of primary osteoporosis and low bone mass in adults. In the new guideline, ACP recommends bisphosphonates as initial pharmacologic treatment to reduce the risk of fractures in males and postmenopausal females diagnosed with primary osteoporosis.

Andrew Hachadorian

Osteoporosis, bone mass, bisphosphonates, fractures, dual-energy x-ray absorptiometry, DXA, serial bone mineral density, BMD, osteoporotic fractures, hip fractures, denosumab

Tue, 01/03/2023 - 10:55 AM EST

Tue, 01/03/2023 - 10:56 AM EST

1

pharmacologic_treatment_of_primary_osteoporosis_to_prevent_fractures_in_adults_2023.pdf

{"Author":"Andrew Hachadorian","Creator":"Microsoft\u00ae Word for Microsoft 365","CreationDate":"2023-01-03T10:55:34-05:00","ModDate":"2023-01-03T10:56:32-05:00","Producer":"Microsoft\u00ae Word for Microsoft 365","Title":"Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults","Subject":"","Keywords":"Osteoporosis, bone mass, bisphosphonates, fractures, dual-energy x-ray absorptiometry, DXA, serial bone mineral density, BMD, osteoporotic fractures, hip fractures, denosumab","Pages":1}

2023